Deals· August 1, 2026 · 20 min read
Gilead's $5B Tubulis Buyout: Deal Anatomy & NaPi2b ADC Platform
By Ran Chen#M&A#ADC#FDA Approval
Topic
ADC
Antibody-drug conjugates, oncology evidence, label expansion, payer access, coding, and commercialization.
Deals· July 23, 2026 · 17 min read
Novartis Ends Last Big-Pharma ADC Holdout: The $1.5B Myricx Deal
Pipeline· July 22, 2026 · 17 min read
Antibody-Drug Conjugate (ADC) Clinical Trials by the Numbers (2026)
By Ran Chen#ADC#Oncology#Clinical Trials
Pipeline· May 30, 2026 · 11 min read
ASCO 2026 practice-changing results with formulary implications
Pricing & Access· May 30, 2026 · 11 min read
Datroway TNBC coverage guide: TROP2 ADC access and coding
By Ran Chen#ADC#Breast Cancer#Prior Authorization
Approvals· May 28, 2026 · 7 min read
Decnupaz coverage guide: pivekimab sunirine access in BPDCN
Pipeline· May 27, 2026 · 7 min read
Antibody-drug conjugate access landscape: ADC coverage and pipeline watch
By Ran Chen#ADC#HER2#Prior Authorization
Pricing & Access· May 27, 2026 · 9 min read
Padcev plus Keytruda urothelial cancer access guide
Pricing & Access· May 27, 2026 · 9 min read
Trodelvy access guide for breast cancer coverage
By Ran Chen#Oncology#ADC#Prior Authorization